No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

116 trials linked to this intervention

116

Total Trials

Recruiting

With Results

Recent Trials

Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)

NCT00000437Phase 4Completed60 enrolled

Naltrexone Treatment for Alcoholism

NCT00000438Phase 4Completed192 enrolled

Drug Therapy for Alcohol Detoxification

NCT00000441Phase 4Completed

Naltrexone for Relapse Prevention

NCT00000442Phase 4Completed57 enrolled

Timing of Smoking Intervention in Alcohol Treatment (Nicotine Patch)

NCT00000444Phase 4Completed500 enrolled

View all 116 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

The conditional stimulation of rat organic cation transporter 2, but not its human ortholog, by mesoridazine: the possibility of the involvement of the high-affinity binding site of the transporter in the stimulation.

Hyung Sungwoo, Pyeon Wonji, Park Ji Eun et al. · J Pharm Pharmacol · 2017

PMID: 28809437Observational

Determination of mesoridazine by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in rats.

Im So Hee, Park Myoung Joo, Seo Hyewon et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2014

PMID: 24732149Observational

Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.

Dorado Pedro, Peñas-LLedó Eva M, de la Rubia Alfredo et al. · Pharmacogenomics · 2009

PMID: 19604081Observational

Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.

Salih I S M, Thanacoody R H K, McKay G A et al. · Clin Pharmacol Ther · 2007

PMID: 17410120Observational

Involvement of Proton-Coupled Organic Cation Antiporter in Human Blood-Brain Barrier Transport of Mesoridazine and Metoclopramide.

Debori Yasuyuki, Igari Tomoko, Nakakariya Masanori et al. · Biol Pharm Bull · 2024

PMID: 39414441Other

Combination of experimental and in silico methods for the assessment of the phototransformation products of the antipsychotic drug/metabolite Mesoridazine.

Wilde Marcelo L, Menz Jakob, Leder Christoph et al. · Sci Total Environ · 2018

PMID: 29055596Other

Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel.

Su Zhi, Martin Ruth, Cox Bryan F et al. · J Mol Cell Cardiol · 2004

PMID: 14734057Other

Diastereotopic analysis of mesoridazine besylate (Serentil).

Morrow Ryan J, Millership Jeff S, Collier Paul S · Chirality · 2004

PMID: 15290689Other

Topically applied mesoridazine exhibits the strongest cutaneous analgesia and minimized skin disruption among tricyclic antidepressants: The skin absorption assessment.

Liu Kuo-Sheng, Chen Yu-Wen, Aljuffali Ibrahim A et al. · Eur J Pharm Biopharm · 2016

PMID: 27260201Preclinical

No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.

Dorado Pedro, Berecz Roland, Peñas-Lledó Eva M et al. · Eur J Clin Pharmacol · 2007

PMID: 17345072Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Mesoridazine (substance)
SNOMED CT: 372852001
UMLS CUI: C0025497
RxNorm CUI: 6779

Clinical Data

This intervention maps to 6 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

116

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.